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Background: Marek’s Disease (MD) is a hyperproliferative, lymphomatous, neoplastic disease of chickens caused by
the oncogenic Gallid herpesvirus type 2 (GaHV-2; MDV). Like several human lymphomas the neoplastic MD
lymphoma cells overexpress the CD30 antigen (CD30hi) and are in minority, while the non-neoplastic cells (CD30lo)
form the majority of population. MD is a unique natural in-vivo model of human CD30hi lymphomas with both
natural CD30hi lymphomagenesis and spontaneous regression. The exact mechanism of neoplastic transformation
from CD30lo expressing phenotype to CD30hi expressing neoplastic phenotype is unknown. Here, using microarray,
proteomics and Systems Biology modeling; we compare the global gene expression of CD30lo and CD30hi cells to
identify key pathways of neoplastic transformation. We propose and test a specific mechanism of neoplastic
transformation, and genetic resistance, involving the MDV oncogene Meq, host gene products of the Nuclear
Factor Kappa B (NF-κB) family and CD30; we also identify a novel Meq protein interactome.
Results: Our results show that a) CD30lo lymphocytes are pre-neoplastic precursors and not merely reactive
lymphocytes; b) multiple transformation mechanisms exist and are potentially controlled by Meq; c) Meq can drive
a feed-forward cycle that induces CD30 transcription, increases CD30 signaling which activates NF-κB, and, in turn,
increases Meq transcription; d) Meq transcriptional repression or activation of the CD30 promoter generally
correlates with polymorphisms in the CD30 promoter distinguishing MD-lymphoma resistant and susceptible
chicken genotypes e) MDV oncoprotein Meq interacts with proteins involved in physiological processes central to
lymphomagenesis.
Conclusions: In the context of the MD lymphoma microenvironment (and potentially in other CD30hi lymphomas
as well), our results show that the neoplastic transformation is a continuum and the non-neoplastic cells are
actually pre-neoplastic precursor cells and not merely immune bystanders. We also show that NF-κB is a central
player in MDV induced neoplastic transformation of CD30-expressing lymphocytes in vivo. Our results provide
insights into molecular mechanisms of neoplastic transformation in MD specifically and also herpesvirus induced
lymphoma in general.
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Lymphomas are the 6th leading cause of cancer mortality
in the USA especially in patients younger than 40 years
[1,2]. More than 11% of human lymphomas overexpress
the CD30 antigen (a.k.a. Hodgkin’s Disease antigen, or
Tumor Necrosis Factor Receptor Superfamily Member 8
[TNFRSF8])—this includes all Hodgkin’s lymphomas
(HL) and some non-Hodgkin’s lymphomas (NHL); e.g.
anaplastic large cell lymphoma (ALCL), primary cutane-
ous anaplastic large cell lymphoma (PCTL), adult T-cell
leukemia/lymphoma (ATLL), peripheral T-cell lymph-
oma (PTCL), natural killer (NK)/T-cell lymphoma, nasal
and enteropathy type T cell lymphoma [3-5]. Natural
“spontaneous” animal models that mimic the human
lymphoma microenvironment, and have a functional im-
mune system, are invaluable tools to understand lymph-
oma development [6]. Marek’s Disease (MD)—a CD4+ T
cell lymphoma of chickens caused by the Gallid herpes-
virus type 2 (GaHV-2; MDV)—is a unique natural ani-
mal model for herpesvirus induced lymphomagenesis in
general and CD30hi lymphomas specifically [7].
CD30 overexpression is an evolutionarily conserved
process in neoplastic transformation in human and
chicken lymphomas of different etiologies [7]. Like
human CD30hi lymphomas, MD lymphomas are a het-
erogeneous mix of a minority of neoplastically trans-
formed lymphocytes (CD30hi), surrounded by majority
of non-transformed (CD30lo) lymphocytes [8,9]. Physio-
logically, CD30 signaling modulates cell survival and
death; however, in CD30hi lymphoma cells, it preferen-
tially promotes cell survival [10,11]. CD30 overexpres-
sion (in both human and MD lymphomas) induces a T
helper 2 (Th-2) or regulatory T cell (T-reg)-like cytokine
microenvironment, which is antagonistic to cell
mediated immunity, immune evasive [6,12,13], and pro-
motes lymphomagenesis [8,14,15].
CD30 signaling activates the transcription factor Nu-
clear Factor-kappa B (NF-κB), which regulates genes
associated with cell survival, proliferation, programmed
cell death (PCD), stress and immunity [16]. Constitutive
NF-κB activation, due to CD30 overexpression and lig-
and dependent/independent signaling, results in neo-
plastic transformation in human CD30hi lymphomas
[1,17]. The human oncogenic viruses Epstein-Barr virus
(EBV/HHV-4) and Kaposi’s sarcoma-associated herpes-
virus (KSHV/HHV-8) both subvert NF-κB activation via
the CD30 signaling pathway when transforming cells—
as MDV does in the chicken [18]. This suggests that the
CD30 signaling pathway is fundamental, or at least
highly beneficial to herpesvirus survival [18].
MD transformed lymphocytes have increased MDV
oncogene “Meq” expression [19]. Meq is essential for
MDV lymphomagenesis [20,21] and a positive correl-
ation exists between Meq and CD30 expression [18].Also, the chicken CD30 promoter has 15 known Meq
binding sites, and Meq’s promoter has at least one NF-
κB binding site [18]. We hypothesize that a feed-forward
loop exists, with Meq induced CD30 overexpression,
constitutive NF-κB activation with resulting increased
Meq transcription—favoring neoplastic transformation.
Here we show, using MD lymphocytes isolated directly
ex vivo that they are either neoplastically transformed
and express high levels of CD30 (CD30hi) or are non-
transformed and express low levels of CD30 (CD30lo)
that: 1) neoplastic transformation is a continuum and
the CD30lo lymphocytes within the tumor microenviron-
ment are pre-neoplastic; 2) as the lymphocytes become
more neoplastically transformed they become more
immune-evasive; 3) the MDV oncogene Meq, has a dir-
ect role in this process and 4) NF-κB has a central role
in this neoplastic transformation. In vitro, we show that:
1) a feed forward loop exists in which Meq activates
CD30 transcription resulting in CD30 protein overex-
pression, which induces NF-κB activation which acti-
vates Meq transcription (in addition to other genes); 2)
Meq and NF-κB transcriptional effects on the Meq pro-
moter can be additive and that NF-κB isoforms have dif-
ferent effects; 3) Meq transcriptionally activates or
represses the CD30 promoter depending on whether it
is derived from a MD-susceptible or -resistant genotype;
4) the Meq interactome consists of proteins involved in
physiological processes central to lymphomagenesis.
Results and discussion
Because the proteome directly affects phenotype, but the
transcriptome merely influences the proteome and thus
may only indirectly affect the phenotype [22-24], we
based our systems biology model of neoplastic-
transformation in MD on the differences between the
transformed CD30hi, and the non-transformed CD30lo
MD lymphocytes proteomes. We isolated CD30hi and
CD30lo lymphocytes directly ex vivo at >99% purity as
described [12]. All comparisons and differential expres-
sions are expressed as CD30hi relative to CD30lo lym-
phocytes (at p < 0.05). Of the 11,958 proteins we
identified (Additional file 1, PRIDE Accession # 14847–
14852) 1,588 proteins were significantly increased, and
808 proteins had significantly decreased expression in
the CD30hi lymphocytes.
Functional modeling
To visualize the differences between the CD30hi and
CD30lo lymphocytes proteomes (Figure 1) in terms of
well-studied cancer pathways, the differential protein ex-
pression data (Additional file 1) was manually mapped
to the cancer specific pathway “Pathways in cancer”
from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [25] (Figure 1). This specific KEGG pathway is
Figure 1 Proteomics based network model showing differential expression of proteins in canonical cancer pathways and the intricate
involvement of Meq, via hypothesized CD30-NF-κB-Meq pathway. Canonical Network model of proteome data using differential proteomic
expression (CD30hi compared to CD30lo) mapped against cancer specific KEGG pathway “Pathways in cancer” and further modified by adding
published Meq interaction and hypothesized Meq-CD30-NF-κB-Meq pathway. Light black solid lines indicate direct interaction, dotted lines
indicate indirect interaction. Red dotted lines indicate our hypothesized CD30-NF-κB-Meq pathway. Literature based Meq interacting proteins are
indicated by dark black lines originating from Meq.
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and so provides a comprehensive overview of the mo-
lecular signatures of CD30hi and CD30lo lymphocyte
proteomes. We further modified the KEGG pathway by
adding the Meq oncoprotein, previously published Meq
interacting proteins, and our hypothesized Meq-CD30-
NF-κB feed forward loop.
A mixed pattern emerged with protein levels in-
creasing, decreasing and not changing. However, in
several of the pathways described below, key regula-
tory proteins were differentially expressed: NF-κB,
IKK, VEGF, MDM2, CD30, HSPA2, MYC, JUN, TGFβ,
and Meq were increased; whereas, RB, PENK, and
BRCA2 were decreased. This indicates that neoplastic
transformation is being regulated by these key pro-
teins. The MDV oncoprotein Meq interactions, and
our hypothesized Meq-CD30-NF-κB feed-forward loop,
suggest that Meq interacts with several key proteins
involved in neoplastic transformation, immune evasion
and cell survival.Ingenuity Pathway Analysis (www.ingenuity.com,
IPA)-based functional grouping of the significantly
expressed pathways (data not shown) confirmed our pre-
vious findings [26] that PCD was perturbed and integrin
signaling was increased in CD30hi cells. IPA analysis also
indicated that PCD signaling, molecular mechanisms of
cancer, NF-κB activation by viruses, p53 signaling,
PPARα/RXRα activation, PTEN signaling, BRCA1 in
DNA damage, VEGF signaling, Wnt/β-catenin signaling,
lymphotoxin β receptor signaling (important in non-
canonical NF-κB activation pathway induction), TGF-β
signaling (insensitivity to antigrowth signals) and nitric
oxide signaling (important in angiogenesis) were acti-
vated in both CD30hi and CD30lo cells. The physiological
processes that the pathways affect, and the differences
between the cell types, suggest that the CD30lo lympho-
cytes are pre-neoplastic precursors of the CD30hi
lymphocytes.
To this point our modeling was on a global scale.
Using the same data (Additional file 1), we next tested
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ing to essential steps of neoplastic transformation in the
transition of CD30lo to CD30hi lymphocytes:
a)Growth signals are perturbed: Growth factors control
cell division and their deregulation contributes to
neoplasia. IGF1 increases cell cycle and prevents
PCD [27] and it is transactivated by GH1 (via STAT5
[28]). Growth hormone GH1, which interacts with
MDV’s SORF2 protein, is a suggested MD resistance
gene [29]; however, both GH1 and SORF2 protein
expression were the same in the CD30lo and in
CD30hi cells. Our results suggest that the growth
factor effects on MD resistance identified previously
(32), may either occur at an earlier stage of MD, or
are unrelated to lymphomagenesis. Growth factor
receptors activate pathways for growth, proliferation,
differentiation, survival, migration, angiogenesis and
metabolism and, in contrast to the growth factors,
the growth factor receptor proteins HGFR (MET)
and PDGFR were increased. HGFR, which binds FAS
and inhibits PCD, is also over-expressed in human
CD30hi lymphomas [30-34] as is PDGFR [35-37].
PDGFR over-expression can also make cells hyper-
responsive to PDGF [36]. CD30hi lymphocytes also
had 4-fold more nuclear-located ERBB protein and
over-expression and nuclear localization of ERBB-1
and −2 are common in tumors [38].
Growth factor receptors activate the MAPK, JAK-
STAT, and, through PI3K/AKT, the MTOR signaling
pathways. The MAPK pathway activates JUN, FOS
and MYC, and the JAK-STAT pathway activates
VEGF and both promote proliferation and
angiogenesis. In the MAPK pathway, HRAS was
decreased and JUN and MYC were increased. JUN
mRNA was decreased and, as JUN transcription is
autoregulated by JUN protein (45), and JUN
heterodimerizes with Meq. We suggest that even
though total JUN protein was increased in CD30hi
lymphocytes, it is not available for auto-
transactivation, an alternative possibility is that as
JUN protein is stabilized by post-translational
interactions with Meq, the JUN mRNA may not
actually reflect the total JUN protein levels [39].Activated PI3K phosphorylates AKT, which in turn
activates IKKA, MTOR (FRAP1) and MDM2 and inhi-
bits FKHR, CASP9, BAD, p27 and p21 genes [40-42].
IKKA, MDM2, CASP9 increased, though FKHR, p27,
p21, MTOR (FRAP1) did not. PTEN inhibits PI3K sig-
naling in the absence of growth factors, and STK11
(LKB1) inhibits MTOR activity when ATP is low [40].
Consequently, cells lacking functional PTEN or STK11
exhibit deregulated, but constitutive, signaling toMTOR, resulting in cancer (46, 47). Though PTEN pro-
tein was not differentially expressed, STK11 protein (a
tumor suppressor) decreased. From an antigrowth signal
perspective, RB1 sequesters the E2F transcription factors
transcriptionally-repressing genes essential for G1 to S
phase cell cycle progression [42,43] and RB1 was
decreased suggesting increased cell cycle progression in
CD30hi lymphocytes supporting our previous work [15].
b) Cell cycle and PCD are dysregulated: Cell cycle
regulation and PCD are intimately linked. The proto-
oncogenic WNT proteins were increased and WNT
activation leads to CTNNB protein nuclear
translocation. CTNNB also increased and was 80%
nuclear. Canonically, CTNNB translocation results
in TCF-mediated activation of the proto-oncogene
MYC (pro-cell cycle/anti-PCD), anti-PCD protein
SURVIVIN and the G1/S-specific cyclin-D1
(CCND1) [44,45]. BCL2 blocks apoptosis in many
diverse cancers, and in-vitro work using a rodent
fibroblast cell line, suggests that MDV Meq increases
BCL2 mRNA [46], and proposed that this is
important in MD lymphomagenesis. In our work
from MD lymphocytes in vivo, BCL2 protein was
unchanged suggesting that any BCL2 functional-
deregulation may occur prior to the CD30lo to
CD30hi transition in the lymphoma environment.
HSP70 inhibits both the intrinsic and the extrinsic
PCD mechanisms and is frequently increased in
malignant tumors [47-50], Meq also co-localizes
with HSP70 in the nucleus [49] where HSP70
mediates Meq’s interaction with TP53 and CDK2
[49]. In agreement, we found HSP70 protein was
increased and was 100% nuclear. Decreased PENK
increases anti-PCD-gene transcription [51] and
PENK protein was decreased by half, and its nuclear
distribution decreased by 70%, suggest decreased
PCD possibly mediated by Meq (see below).
c) Telomeres are dysregulated: Shortened telomeres
promote PCD and the telomerase complex maintains
telomere length in cancer [52]. The telomerase
complex has two core components: telomerase RNA
(TR; the template for telomere repeat synthesis) and
the enzyme TERT. CD30hi lymphocytes have 20%
more nuclear TERT. Furthermore, POT1, a protein
also required for telomerase maintenance [53,54],
was also increased in CD30hi cells.
d) Angiogenesis is increased: Tumor cells can induce
neo-angiogenesis or vasculogenesis [55], and pro-
angiogenic VEGF was increased and anti-angiogenic
MMP9 remained unchanged, suggesting endothelial
cell proliferation and angiogenesis.
e) Metastasis is promoted: Metastasis a primary cause
of cancer mortality and part of MD pathogenesis.
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Figure 2 Proteomics based Gene ontology (GO) based
quantitative modeling of cellular immunophenotypes of CD30lo
and CD30hi cells. Quantitative modeling of the CD3lo and CD30hi
lymphocyte proteome by Gene Ontology Biological Processes (A)
and immunophenotype using GO-modeler [12] as described in
methods [3].
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consistently increased in metastatic cancers [57].
EZR complexes with NF2, links membrane proteins
and the actin cytoskeleton, and regulates cell
survival, adhesion and migration [58]; it also
complexes with CD44 [59] and MET [60,61] to
promote metastasis. EZR, NF2, CD44 and MET
were all increased suggesting that metastasis is more
a function of CD30hi, than CD30lo, lymphocytes and
this is consistent with human CD30hi lymphomas.
f ) Immune evasion mechanisms are increased:
MAN1A2, (which induces T-reg cell migration and
prevents T cell priming [62]), was increased and this
supports our previous contention that as neoplastic
transformation proceeds, a T-reg-like phenotype is
induced [3,6,12]. IRG1 protein and mRNA (p < 0.06)
were decreased in the CD30hi cells. Expression of
IRG1 mRNA is induced by pro-inflammatory
cytokines and lipopolysaccharide after bacterial
infection of macrophages/monocytes [63]. There is
very limited published literature about IRG1’s
functions in lymphomas, however, recent studies in
MD literature have suggested that IRG1 may be
associated with apoptosis and is potentially pro-
apoptotic [64]. By searching the EBI Gene Expression
Atlas (http://www.ebi.ac.uk/gxa/) we found that
IRG1 mRNA is decreased in some human and
mouse lymphoid neoplasia datasets also—as is its
regulator leukemia inhibitory factor (LIF; which was
decreased at the protein level in our data). We
speculate that both LIF and IRG1 are worthy of
investigation in future for a role in neoplastic
transformation and anti-apoptosis in MDV
pathogenesis [64]. The data that we found in the EBI
Gene Expression Atlas shows that such a mechanism
may exist in human disease also, but this data has
not yet been recognized, nor the hypothesis tested,
by human medical research.
g) Epigenetic regulators are activated: DNA methyl
transferases (DNMT1, DNMT3A and DNMT3B),
histone acetyltransferase (HAT) and histone
deacetylases (HDAC)] are implicated in human and
MD lymphomas [65] and HDAC-8 and −10 mRNAs,
and DNMT3B and HDAC9 proteins, were increased.
h)MDV proteins other than Meq are involved and have
altered expression: The MDV DNA replication genes
thymidine kinase and deoxyuridine triphosphatase
(73–75) decreased, in agreement with MDV being
latent; but, in addition to Meq being increased, so
were the envelop glycoproteins D, I, K, the major
capsid protein and nuclear egress lamina protein –
all are structural proteins important for MDV
horizontal transmission. This supports our previous
work that CD30hi lymphocytes have the highest loadin lymphomas [66] and suggests lateral MDV cell-
cell transmission within the lymphoma. We
speculate, that MDV, like EBV [67] has more than
one “latency program” and that the immuno-
suppressive lymphoma environment “permits” MDV
to produce more proteins than it would in other
environments. We also suggest, based on our data
above, that, as in EBV [68], epigenetic regulation
plays a role in latency programs.
Biological processes associated with neoplastic
transformation and immune-evasion
At a higher level, the Gene Ontology (GO) allows explicit
modeling not limited by canonical pathways [69]. We
compared CD30hi and CD30lo lymphocyte proteomes,
using quantitative GO biological process (BP) modeling
(Figure 2A), for the biological processes inherent in neo-
plasia as described [3]. Although both the CD30hi and
CD30lo lymphocytes have pro-neoplastic phenotypes (i.e.
pro-cell activation, pro-angiogenic, anti-PCD, pro-cell
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pro-migration, pro-proliferation, pro-oxidative stress and
pro-telomerase maintenance) the CD30hi cell proteome
is more pro-neoplastic than the CD30lo.
Next, we compared the CD30hi and CD30lo lymphoma
cell immune-phenotypes [6,12] (Figure 2B). We have
identified the MD lymphoma microenvironment as pre-
dominantly T-reg-like [6] but did not differentiate which
lymphocytes were contributing to the phenotype. Here
we show that the CD30hi and CD30lo cell proteomes
have similar T-reg-like phenotypes and the CD30hi lym-
phocytes are more Th-2-biased, but less Th-1 and pro-
inflammatory-biased, than the CD30lo lymphocytes. This
is consistent with a model of increased CD30 expression
and signaling promoting immune-evasion [9,70].
Transcriptional regulation
To identify potential direct transcriptional proteome
regulation, we used the 44 K Agilent chicken microarray
[71,72] to quantify mRNA and micro (mi)RNA
(Additional file 2) isolated from the same CD30hi and
CD30lo lymphocytes which were used for proteomics
and compared transcriptional fold changes with protein
fold changes (Figure 3A; Additional file 3). Overall there
was poor fold change correlation between mRNA and
protein for 4592 host gene products (R2 = 0.0007). Next,
to identify the key regulatory proteins responsible for
neoplastic transformation, all the gene products which
were differentially expressed in the same direction at
both mRNA and protein levels were selected for further
analysis. There are 88 gene products whose mRNA and
protein fold changes were both significant and direction-
ally consistent with each other (i.e. concordant) and
these have an overall positive correlation (Figure 3B, R2
= 0.5581). Of these, on cross referencing with the pub-
lished literature, revealed that BRCA2, CD30, CD40L,
CST3 and PENK are known to be involved in human
CD30hi lymphomas [17,51,73-79] and, except for CD30,
all had decreased expression in CD30hi cells. BRCA2 is
involved in error-free DNA-damage repair and
decreased BRCA2 expression results in erroneous join-
ing of DNA breaks [73]; CD30 is over-expressed in all
human HL and some NHL [74,80]; CD40L prevents
caspase-dependent and -independent PCD in HL cell
lines [75]; CST3 is secreted by neoplastically trans-
formed cells [76], inhibits neovascularization [81] and,
via its inhibitory effect on cathepsin B and S, inhibits
tumor invasion and metastasis [82] and is a biomarker
in humans for NHL relapse [77]. CST3’s mRNA and
protein decrease in MD CD30hi lymphocytes is consist-
ent with human and murine lymphomas [77-79] and
decreased CST3, enhances angiogenesis, tumor burden,
tumor cell proliferation and tumor invasion [83] and
also leads to increased expression of pro-neoplasticgrowth factor like IGF1 and FGF1 in mice [84]. In cells
over-expressing NF-κB, and in coordination with TP53,
PENK induces PCD [51], and so its decreased expression
favors neoplasia.
Specific GO-based BP modeling of these 88
concordantly-expressed genes shows that they are
involved in BPs known to be perturbed in, and central
to, neoplastic transformation (Figure 3C): 25% are
involved in proliferation, 20% in cell cycle and ~ 10% in
regulating PCD, cell-cell adhesion (essential for metasta-
sis), innate and adaptive immunity, oxidative stress,
DNA damage response and glucose metabolism.
We next ranked the genes based on their mRNA: pro-
tein expression correlation, and then grouped them into
pentiles and compared the distribution of BP by pentile
(Figure 3D-i). Across the five pentiles gene expression
regulation was the most dominant BP; the next two big-
gest BP groups, consistent across the five pentiles, were
proliferation and cell cycle. Both proliferation and cell
cycle are central to lymphoblastoid cell physiology and
neoplastic transformation. The proliferation: cell cycle
and proliferation: PCD ratios were both 4.5 in pentile 1.
In contrast the mean ratios for the other four pentiles
were 1.4 (range 0.6 to 3). The high correlation between
mRNA and protein expression, coupled with predomin-
ance of genes involved in cell proliferation in pentile 1
(compared to other four pentiles), suggested that pentile
1 genes may be transcriptionally regulated via Meq and
this would favor neoplastic transformation.
We next identified the numbers of putative canonical
MDV Meq binding sites (searched for the core AP-1,
MERE I and MERE II motifs as described in [85]) in
each of the 88 concordantly-expressed genes’ promoters
(2.5 Kb 5’ of the ATG) as described [86]. Genes in pen-
tile 1 (with mRNA: protein expression ratios closest to
1:1) have more Meq binding sites in their promoters
than those in the other pentiles, which do not differ
from each other (Figure 3D-ii, Additional file 4). Of the
five concordant genes previously implicated in lympho-
magenesis in other species, BRCA2, CD30, CD40LG,
and PENK are in pentile 1 with a group mRNA:protein
expression correlation (R2) of 0.92, suggesting direct
transcriptional regulation by Meq. In contrast, CST3 is
in pentile 4 with a large decrease in protein but small
decrease in mRNA. It is possible that CST3 is regulated
at the level of miRNA; an alternative possibility is that
CST3 is a secreted protein so a small decrease in mRNA
could result in a large decrease in cellular protein and,
consistent with our observation, most CST3 was located
in the predominantly soluble differential detergent frac-
tion 1. Notably, IRG1 was in pentile 1, and has the most
Meq binding sites of all the concordant genes (51), all of
which are MERE II binding sites, suggesting Meq
induced transcriptional repression, and a central role in
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Figure 3 mRNA and protein correlation and GO based
modeling of 88 concordantly expressed host gene products.
Overall correlation (R2 = 0.0007) of protein and mRNA fold changes
in CD30hi, compared to CD30lo lymphocytes ((A); n = 4592). Overall
correlation for gene products differentially expressed in the same
direction at both mRNA and protein levels showing higher
correlation (n = 88, R2 = 0.5581). The triangles indicate genes known
to be involved in CD30hi lymphomas, and have mRNA: protein
correlation close to 1 (R2 = 0.92). CST3 is also involved in in CD30hi
lymphomas but has very low mRNA: protein correlation. (B). Gene
Ontology (GO) Biological Processes (BP) associated with the
concordantly-expressed gene products indicates involvement in
cellular processes perturbed in neoplastic transformation (C).
Concordant gene products were ranked based mRNA: protein
correlation and then grouped into pentiles and distribution of GO
BP by pentile were compared. Cell cycle and proliferation are
disproportionately represented in pentile 1 (D-i). Pentile 1 genes
have more putative Meq binding sites in their promoters than genes
in the other pentiles (mean ± sem) (D-ii).
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in pentile 1 are critical for neoplastic transformation.
miRNAs are non-coding post transcriptional repres-
sors potentially important in neoplasia and we identified
152 expressed chicken miRNAs (Additional file 2). Of
these, nine (gga-mir-1b, gga-mir-7, gga-mir-7b, gga-mir-
10b, gga-mir-31, gga-mir-130b, gga-mir-204, gga-mir-
215, gga-mir-489) are increased, and five (gga-mir-223,
gga-mir-124b, gga-mir-140, gga-mir-183, gga-mir-222a)
are decreased in CD30hi cells. In MDV infected CEFs,
gga-mir-29b,-196,-133a,-10b,-30d were increased, and
gga-mir-let-7a, 7b, 7f and gga-mir-1a, mir-130a were
decreased [87]; of these only gga-mir-10b was increased
in our data. This suggests that the in vivo lymphoma en-
vironment where MDV is “latent” is functionally quite
different from a lytic fibroblast culture. In vitro, gga-
mir-221 and gga-mir-222 inhibit expression of CDK in-
hibitor protein p27/KIP1, but p27/KIP1 protein was
increased in the MDV transformed lymphoblastoid cell
line MSB-1 [88]. In our results gga-mir-221 was not dif-
ferentially expressed and gga-mir-222a was decreased:
and this is consistent with our data that p27/KIP1 pro-
tein is not differentially expressed. gga-mir-26a inhibited
IL-2 mRNA and was decreased in seven MD trans-
formed cell lines [89,90], but again in our dataset, nei-
ther gga-mir-26a nor IL-2 were differentially expressed
and neither was IL-2 protein.
We used the miRDB [91,92] to identify novel miRNA
targets (Additional file 2), and we found that the 9 differ-
ent miRNAs that increased in CD30hi lymphocytes tar-
get several genes associated with neoplastic processes
(Additional file 2): gga-mir-204 targets FAS apoptosis in-
hibitory molecule 2, RAB22A (a RAS oncogene family
member) and HDAC 9; gga-mir-489 targets FAS asso-
ciated factor 1 (FAF1) and gga-mir-7 targets RAS related
viral oncogene homolog 2. Except FAF1 (which was
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so we cannot confirm the upregulated miRNA’s potential
effects on neoplasia in CD30hi cells. Notably however,
gga-mir-183 which targets EZR mRNA (which did not
change), was decreased and EZR (important in metasta-
sis) protein increased; i.e. we suggest that one reason for
the increase in EZR protein is decreased gga-mir-183
translation-inhibition.
CD30hi lymphocytes have increased levels of activated
NF-κB
Constitutive NF-κB activation is a proposed mechan-
ism by which overexpressed CD30 induces neoplastic
transformation in human HL and NHL and in MD
[18]. Our global proteomics modeling data (Figure 1),
Ingenuity Pathway analysis, and mRNA-protein correl-
ation data (Figure 3) further suggested a direct role of
Meq and NF-κB in MD transformation. CD30 activates
NF-κB via both canonical and non-canonical pathways
and both ligand-dependently and -independently [11].
In the canonical pathway, IκB inhibitors, IκBα, IκBβ,
and IκBE (not identified in chicken) are phosphorylated
by IκB kinases (IKK) and ubiquitinated by ubiquitin
ligase (BTRCP). Proteasomal degradation of IκB inhibi-
tory proteins releases NF-κB dimers, which translocate
to the nucleus and transactivate target genes [93]. In
the non-canonical pathway, p100 (NF-κB2 precursor
protein) acts as IκB inhibitory molecule and an IKKα
homodimer acts as the main activator: IKKα phosphor-
ylates p100, resulting in proteasomal degradation of in-
hibitory C-terminal domain (IκBδ), which generates
the p52 subunit (functional NF-κB2 protein) and
dimerizes with RelA or RelB to form functional NF-κB
dimers [94].
We found that NF-κB p50 (functional NF-κB1), p65
(RelA) and RelB and IKKα proteins all increased in
CD30hi lymphocytes (Figure 4A) and most p50 and
all p65 protein (which form the most common and
abundant classical dimers) were nuclear (Figure 4B,
Additional file 1). NF-κB signaling is controlled by nega-
tive feedback via IκBα and A20/TNIP2 (tumor necrosis
factor alpha-induced protein 3 [TNFAIP3] in chicken)
transcriptional induction [95] and we found TNFAIP3
mRNA and protein unchanged but IκBα mRNA
decreased, suggesting that this negative feedback mech-
anism is suppressed. The TNFAIP3 and IκBα promoters
have 18 (all MERE II) and 9 (3 MERE I and 6 MERE II)
predicted Meq-binding sites, respectively, which suggest
that MDV has evolved to maintain NF-κB activation.
Not only do CD30hi lymphocytes have more of all NF-
κB isoforms but more are nuclear (Figure 4B, Additional
file 1), again suggesting NF-κB activation. Furthermore
in CD30hi lymphocytes, most IKKα is phosphorylated at
the canonical residues that regulate proteasome-mediated degradation [96,97] and destabilization [98-
100], whereas the opposite occurred for IKKα in CD30lo
lymphocytes (Figure 4C, Additional file 1).
NF-κB transactivates Meq transcription in vitro
Because we proposed a feed-forward loop model of in-
creasing Meq and CD30 expression [18] and our glo-
bal analysis suggests that NF-κB is central in MD
lymphomagenesis, we tested NF-κB isoforms’ transacti-
vation potential on the Meq promoter using in vitro
transcription reporter assays (1 Kb 5’ of the Meq
ATG; MDV strain RB-1B). We cloned genes RELA
[p65], NFKB1 [p105/p50] and NFKB2 [p100/p52] and
MEQ (RB-1B) into expression plasmids. SOgE cells
[101] were transfected with the reporter plasmid alone
or in combination with plasmids expressing different
NF-κB isoforms and/or Meq, and transcription was
quantified by QPCR. The three NF-κB isoforms differ-
entially transactivated the Meq promoter (Figure 5A):
p52 was less than p50 and RELA (p65) alone, which
produced similar transcription and were less than p50
and RELA (p65) together (in vivo p50 and p65 form
the classical dimer). Meq alone transactivated the Meq
promoter to similar levels as the positive control cyto-
megalovirus promoter and, when used together with
different NF-κB isoforms, except in the p50-p65 dimer,
it further increased transcription. This finding suggests
that neoplastic transformation in MD depends funda-
mentally on CD30 signaling, and may explain why MD
neoplastically-transformed cell survival (like that of
many human herpesvirus induced lymphomas) critic-
ally depends on the lymphoma environment [6,12,15],
as well as why MDV co-opted the CD30 signaling
pathway.
Meq-dependent differential CD30 promoter transcription
It would be reasonable that differences in the CD30 pro-
moter could confer differences in Meq-induced activa-
tion or repression of the CD30 gene and is of interest to
us because of chicken genotype differences to MD
lymphomagenesis after MDV infection. To measure
Meq-induced CD30 transcription on different CD30
promoters, we first cloned and sequenced CD30 promo-
ters (2431–2438 bp 5’ to the ATG) from two MD-
resistant (lines 61 and N) and four MD-susceptible (line
71, 72, 15I5, and P) genotypes of chickens and sequenced
these. An unrooted phylogenetic tree (Figure 5B) of
these sequences matched the chicken line breeding his-
tory [102]. Lines 6, 7 and 15 are part of 15 lines devel-
oped to study the genetics of avian neoplasia [102]. Line
6 and 7 share common ancestors and this is emulated in
their phylogenetic closeness in our data. Line 15 is also
genetically related to lines 6 and 7 and some line 15
birds were isolated and interbred to produce the 15I
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were produced by further inbreeding. Notably, line 71
was accidentally crossed with 15I5 [102,103], and we in-
dependently identified this event in our phylogenetic
tree, which places Line 71 closer to Line 15I5 than Line
72. Lines N and P are non-inbred lines developed inde-
pendently to study MHC class I-based resistance and
susceptibility to MD [103,104].
After cloning into an expression plasmid, each CD30
promoter was used in in vitro transcription assays using
a Meq-expressing plasmid. Meq altered transcription
from all CD30 promoters’ alleles (Figure 5C) — increas-
ing expression in MD-susceptible lines 71, 72 and P, but
decreasing in the MHC MD-resistant line N and the
very late lymphoma forming [9] line 15I5. MD resistant
line 61 had a small increase in transcription. The trendis that CD30 promoter transcription is associated with
MD lymphoma resistance and susceptibility and that
Meq has host genotype-dependent transcriptional-
activation or repression from the CD30 promoter.
However, although there are 56 single nucleotide poly-
morphisms (SNPs) between the lines’ promoter
sequences (SNPs; NCBI accession numbers: EU000367-
EU000372), none occur in the predicted canonical
Meq binding sites [85] and sequences other than these
previously-described Meq binding sites must be func-
tional. We identified one SNP at position 1754 bp in
15I5 and 1755 bp in line N 5’ of the ATG as a candi-
date; transcription factor binding prediction [105] iden-
tifies the corresponding region in all lines as an AP-1
binding site and we suggest that this SNP could be re-
sponsible for differential function.
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lymphomagenesis
Meq’s functions are modulated by its interacting part-
ners. Here we wanted to identify which proteins were
involved with Meq in the context of DNA binding
and so we used chromatin immunoprecipitaion (ChIP)
using anti-Meq antibodies (rather than traditional
immuneprecipitation), followed by 2D LC-MSMS. We
used MSB-1 MDCC cells as a model for tumor cells. We
identified 31 proteins (PRIDE Accession # 14847–14852,
Additional file 1). We used these 31 proteins and
included previously identified interacting proteins (RB1,
TP53, CTBP, HSP70, JUN, FOS, CDK2, CCND1), to pro-
duce theoretical Meq interactome model. From these,
and using binding proteins from literature, we produced
a Meq interactome model (Figure 6A). Using GO BP
annotations for all the proteins that we modeled in the
network, we next generated a GO BP-based functional
interaction network (Figure 6B). This model suggests
how Meq could interact with proteins associated with
BPs critical to tumor formation such as cell growth, de-
velopment, apoptosis, stress, immunity, transcription,
cell adhesion, energy metabolism, protein metabolism
and transport.
Discussion
Evidence supporting a direct mechanistic connection be-
tween inflammation and cancer has been mounting over
the last decade [106]. The very early pre-lymphoma MD
lesion microenvironments are highly inflammatory [6].
NF-κB is one of the central inflammatory mediators that
is often, and diversely, associated with neoplastic trans-
formation [107] and is a key component of the trans-
formation pathways employed by some herpesviruses.
The KSHV latency-associated proteins vGPCR and
vFLIP, maintain a sustained level of activated NF-κB by
interacting with IKK protein complex and micro RNA
clusters (miR-K1) which inhibit IκBα protein expression,
thus inhibiting the lytic cycle, inducing the latency and
transformation [108-111]. In EBV positive HL the trans-
formed cells overexpress CD30, CD40, RANK receptors
and their cognate ligands are expressed on surrounding
stromal cells. Ligand and receptor interaction (or some-
times ligand independent signaling) activates down-
stream signaling and activation of NF-κB occurs [112].
EBV encoded LMP-1 protein mimics the activated CD40
receptors and results in spontaneous NF-κB activation
[67]. Our “omic” and reductionist experiments in this
work suggest that MDV has also evolved to directly per-
turb the NF-κB signaling pathways while in viral latency.
In vitro MDV Meq induced CD30 expression and per-
sistently activated NF-κB and ex vivo-derived CD30hi
lymphocytes have increased and activated NF-κB pro-
tein. Not only does Meq enhance its own transcription(as previously described [20]) but it also augments NF-
κB transcription. We also suggest that IκBα-mediated
negative feedback, which controls NF-κB activation, is
hypoactive in CD30hi cells. This is consistent with evi-
dence that proinflammatory cytokines induce NF-κB in-
ducing kinase (NIK), which preferentially phosphorylates
IKKα over IKKβ to activate NF-κB [113] and, while re-
cent evidence suggests that IKKβ is primarily activated
in response to pro inflammatory cytokines and microbial
products, IKKα regulates the alternative pathway of NF-
κB activation in lymphoid malignancies [114]. IKKα is
also preferentially activated by the members of TNF re-
ceptor family [115]. Inducing persistent NF-κB signaling
through specific oncoproteins has been demonstrated
for human oncogenic viruses, including EBV, human T
cell leukemia virus type 1, and KSHV [116]. Notably,
EBV LMP-1 effects NF-κB activation through the NF-κB
essential modifier protein which, with IKKα and IKKβ
protein, comprises the IκB kinase (IKK) complex [117]
and we speculate that MDV (possibly via Meq) has
evolved to similarly target the IKK complex.
Regardless, our data supports our hypothesized model
that Meq initiates a self-reinforcing CD30 signaling cycle
resulting in constitutive and aberrant NF-κB activation
and subsequent neoplastic transformation. Herpesviruses
co-evolve with their hosts and and the last common an-
cestor between EBV and MDV was at least
~300 M years ago; MDV, EBV and KSHV have separ-
ately evolved in different target cells the same funda-
mental result by targeting the NF-κB pathway.
Furthermore both MDV Meq and EBV LMP-1 [118] are
expressed as proteins during viral latency and their hosts
mount specific (but weak) cytotoxic T cell responses
against them [18,119,120]. This large evolutionary dis-
tance, combined with the risk incurred by inducing an
immune response, suggests that perturbing NF-κB con-
fers a strong evolutionary advantage and is further evi-
dence consistent with NF-κB essentiality to neoplasia in
general.
Meq is essential for MD lymphomagenesis [21,121]
and promotes neoplastic transformation, anchorage-
independent growth, cell-cycle progression, and anti-
apoptotic activity [46,122-124]. Our in vitro experiments
support Meq’s previously demonstrated transcriptional
regulation of CD30 [18], and, also show that the tran-
scriptional profile generally follows genetic resistance
and susceptibility to MD. A similar phenomenon has
been observed in the CD30 over-expressing human cuta-
neous lymphoproliferative disease lymphomatoid papu-
losis [4,125]: allelic differences in the CD30 transcription
are due to polymorphisms in the human CD30 microsat-
ellite repressor element (located −1.2 kb and −336 bp of
the CD30 promoter) and are associated with disease
progression to lymphoma [125].
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Figure 6 Meq interactome showing previously published and novel interactions identified by ChIP experiments and GO based
modeling of Meq interacting proteins. Meq interactome based on combined data from proteins identified by chromatin immunoprecipitation
(ChIP) experiments (see Methods) and published literature. Differential expression is shown for proteins identified by ChIP. (A). Meq interactome
converted to a GO functional network showing the physiological processes that Meq directly affects are consistent with neoplasia. Circle size
represents effect size based on numbers of proteins associated with that GO annotation (B).
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all species, and often they form the majority cells in
lymphomas. Our work suggests that many of these
non-transformed cells are likely not immune responding
cells in MD [15], but are pre-neoplastic and actively
transforming. Regardless, an immunosuppressive tumor
microenvironment is critical in lymphomagenesis
[6,8,12,14,15,126,127]. In EBV-positive HL, the lymph-
oma microenvironment is T-reg cell rich and the trans-
formed cells secrete immunosuppressive cytokines and
chemokines like IL10, CCL5, CCL20, and CXCL10.
These cytokines and chemokines (may not always
match classical T-reg cytokine profiles [128-130]), at-
tract non-transformed cells [131,132] to the site of lym-
phomagenesis. Similarly, in MD, a recent study has
shown interactions between vIL-8 (a chemotactic factor)
and peripheral CD4 + CD25+ T cells (closely resemble
T–reg phenotype) [12,133], and suggested that vIL-8
may enhance the recruitment of T-reg cells to the
MDV lymphoma microenvironment, which would fur-
ther induce immunosuppression and enhance lympho-
magenesis, supporting our previous observations [6,12].
Here, we have expanded on our previous work [6] and
show that both components of lymphoma microen-
vironment, the CD30hi and CD30lo cells have an overall
T-reg-like phenotype and suggest that CD30lo lympho-
cytes are direct antecedents of CD30hi lymphocytes.
Overall, and in the context of understanding mechan-
istic details of CD30hi lymphomagenesis, our results pro-
vide direct ex vivo-derived support in a natural animal
model for the in vitro results in other species, which
propose that ligand-independent and -dependent CD30
signaling-induced constitutive activation of NF-κB is a
mechanism of neoplastic transformation in Hodgkin’s
disease antigen over-expressing lymphomas [17].Conclusions
Here we identify the neoplastic and non-neoplastic com-
ponent of lymphoma microenvironment using transcrip-
tomics and proteomics followed by Systems Biology
modeling to generates specific hypotheses and then tests
these using reductionist methods. This work provides
evidence that MD neoplastic transformation is a con-
tinuum and the CD30lo lymphoma cells are in various
stages of neoplastic transformation towards CD30hi
phenotype. We hypothesized that MDV uses its Meqoncogene to activate CD30 transcription to achieve con-
stituent NF-κB signaling resulting in cellular instability
and a neoplastic phenotype. Our results show that Meq,
CD30 and NF-κB proteins are overexpressed in CD30hi
cells and that the majority of NF-κB is intranuclear sug-
gesting an activated state. Using transcription reporter
assays, we further show that NF-κB isoforms differen-
tially activate Meq transcription, and Meq and NF-κB
isoforms have additive effects. We also show that Meq
transcriptionally activates or represses the CD30 pro-
moter depending upon the host genotype from which
the promoter is derived. Using ChIP and mass spectrom-
etry we propose a new Meq interactome composed of
proteins which are involved in various biological pro-
cesses inherent in neoplasia. Overall, this study provides
crucial insights into various molecular mechanisms of
neoplastic transformation active within a heterogeneous
lymphoma microenvironment in a natural animal model
with functional immune system.Methods
RNA isolation and microarray experiments
Lymphomas were isolated from white leghorn chickens
infected with MDV GA/22 strain as described [9]. The
CD30hi and CD30lo cells were separated using monoclo-
nal antibody (mAb) AV37 using magnetic activated cell
sorting (Militenyi Biotech) and the purity of sort was
analyzed by flow cytometry as described [66]. RNA was
isolated from 4 replicates of 106 CD30hi and CD30lo
lymphocytes using the TRI ReagentW (Molecular Re-
search Center). The quality of purified RNA was ana-
lyzed using the Agilent 2100 Bioanalyzer (Agilent
Technologies) and RNA was quantified using the Gene-
Spec I spectrophotometer [12,66]. The microarray de-
sign and methods have been described in [71,72]. Briefly,
a 44 K Agilent chicken microarray with dual color
balanced design was used [71]. The genes on the array
included whole chicken genome, 150 chicken micro-
RNAs, [72,134,135], all known MDV and two avian in-
fluenza virus (H5N2 and H5N3) transcripts [72]. 500 ng
of total RNA was reverse transcribed into cDNA with a
T7 sequence inserted in cDNA to drive the synthesis of
complementary RNA (cRNA). The fluorescent labeled
cRNA were purified, hybridized, washed and then
scanned by Genepix 4100A scanner (Molecular Devices)
with the tolerance of saturation setting of 0.005% [72].
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gram (SAS Institute). An approximate F test on least-
square means was used to identify the differentially
expressed genes (p < 0.05) [72]. Data has been deposited
in GEO database, accession numbers (Samples:
GSM689844, GSM689863, GSM689864, GSM689865,
Series: GSE28034).
Protein isolation and protein analysis by 2 dimensional
liquid chromatography electro-spray ionization tandem
mass spectrometry (2D LC ESI MS/MS)
Proteins were isolated from three replicates from (from
different birds) 107 CD30hi and CD30lo cells using differ-
ential detergent fractionation (DDF), trypsin-digested
and analyzed by 2D LC ESI MS/MS using a LCQ Deca
XP Plus (Thermo Fisher Scientific) as described [136].
The experimental mass spectra and tandem mass spectra
were searched (Bioworks, 3.2, Thermo Fisher Scientific),
against an in silico trypsin digested non redundant pro-
tein database which included all annotated chicken and
MDV proteins, with search criteria as described [3]. Pep-
tide identification used decoy database searching and
only peptides identified with p < 0.05 were used for fur-
ther analysis; the differentially expressed proteins were
then identified at p < 0.05 as described [137]. Data has
been deposited in PRIDE database accession numbers
14847–14852. We searched the mass spectra for evi-
dence phosphorylation of the conserved canonical resi-
dues regulating proteasome-mediated degradation
[96,97] and destabilization [98-100] of inhibitor of nu-
clear factor kappa-B kinase (IKK)-α and IKK-β exactly as
for non-modified peptides except that we searched expli-
citly for an additional 80 Da added to unphosphorylated
amino acids [138,139] and calculated probabilities for
phosphopeptides using decoy database searching, the de-
gree of phosphorylation, as described [137,139].
Co-immmunoprecipitation of Meq interacting proteins
Meq interacting proteins were identified by chromatin
immunoprecipitation (ChIP) assays with polyclonal anti-
Meq antibody. MSB-1 cells were grown in Leibowitz’s L-
15 and McCoy 5A media supplemented with fetal bovine
serum (15%), penicillin (100 IU/mL) at 37°C. Cells (107)
were cross-linked with formaldehyde (1%, 10 min, 37°C),
which was added directly to the culture medium. The
culture medium was removed and washed twice with ice
cold phosphate-buffer saline (PBS) containing protease
inhibitor cocktail (Sigma-Aldrich, P8340). ChIP was
done using the Chromatin Immunoprecipitation Assay
kit (Millipore, 17–295) exactly following manufacturer’s
recommendations. Immunoprecipitation was performed
with anti-Meq polyclonal antibody (1:100), incubated
overnight at 4 °C. The DNA/Meq/antibody complexes
were purified using Protein A-agarose/salmon spermDNA beads. The purified complex sample was reverse
cross-linked separating the DNA from Meq and its
interacting proteins. Proteins that were co-
immunoprecipitated with Meq were analyzed and identi-
fied by 2D LC ESI MS/MS as described above.
Plasmid construction
The CD30 promoters (2431–2438 bp upstream from the
ATG start codon) of six different chicken lines (61, 71,
72, 15I5, N and P) were amplified by PCR with Pfu poly-
merase (Promega) and primers CD30-F and CD30-R.
The amplified promoters were ligated into pCRW2.1-
TOPOW (Life Technologies) producing pCRW2.1-CD30
plasmids. The cytomegalovirus (CMV) promoter in the
pd2EGFP-N1 plasmid (Takara Bio) was removed by
digestion with XhoI and VspI; linear DNA was blunt-
ended by T4 DNA polymerase and then self-ligated pro-
ducing pd2EGFPΔCMV. CD30 promoters were released
from the pCRW2.1-CD30 plasmids by EcoRI digestion
and ligated into EcoRI-linearized pd2EGFPΔCMV
resulting in production of the six new expression plas-
mids pd2EGFP-CD30. The Meq promoter (1 kb up-
stream from the Meq start) of the virulent MDV-1 strain
RB-1B was amplified by PCR with primers MEQ-F and
MEQ-R. The promoter was first cloned into pCRW2.1-
TOPOW, then released by EcoRI digestion and re-cloned
into EcoRI-linearized pd2EGFPΔCMV producing the re-
porter plasmid pd2EGFP-Meq. The chicken cDNA en-
coding the NF-κB p100 [140] was released from the
cloning vector pBS KS(+) with HindIII and XbaI and
inserted into HindIII and XbaI-linearized expression
vector pBK-CMV (Agilent Technologies), resulting in
pBK-CMV-p100. The cDNA encoding the chicken NF-
κB p105 [141] cloned in pGEM4 was released by diges-
tion with EcoRI and KpnI and inserted into EcoRI- and
KpnI-linearized pBK-CMV, producing pBK-CMV-p105.
The ankyrin repeats were removed from the 5’ end of
the NF-κB p105 cDNA by digestion with SacI. The
chicken NF-κB p65 cDNA cloned in pTZ18R was
released by digestion with XhoI and MfeI and re-cloned
into XhoI and SmaI-linearized pBK-CMV producing
pBK-CMV-p65. Plasmids were purified using the affinity
chromatography columns (Qiagen) and proper structure
of all the plasmids was verified by restriction enzymes
digest and sequencing.
Promoter assays
The activity of CD30 and Meq promoters was analyzed
in vitro by promoter reporter assays. First, the reporter
gene d2EGFP was placed under the control of the CD30
and Meq promoters and the coding sequences of tran-
scription factors (Meq oncogene, and NF-κB p65, p100
and p105) were cloned into the expression plasmid pBK-
CMV (see Construction of plasmids above). The
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pression plasmids were then transfected into SOgE cells
[101], and the expression of the reporter gene was quan-
titatively measured by duplex real-time PCR as described
below.
SOgE cells were grown in Dulbecco’s modified Eagle’s
minimum essential medium supplemented with 10%
fetal calf serum, penicillin (100 IU/mL), streptomycin
(100 mg/mL) and amphotericin B (0.25 μg/mL) at 37°C
with 5% CO2. Plasmids were transfected in triplicate into
SOgE cells in 24 well plates at 80% confluence using
LipofectinW reagent (Life Technologies) following the
manufacturer’s instructions. Each well was transfected
with 200–400 ng of DNA. To determine the effect of
the Meq oncogene on the activity of the chicken CD30
promoters SOgE cells were transfected with either pUC18
alone (200 ng/well, negative control), pd2EGFP-N1 alone
(200 ng/well, positive control), pd2EGFP-CD30 alone
(200 ng/well, to measure the baseline level of expression
from each of the CD30 promoters), or with a mix of
pBK-CMV-Meq and pd2EGFP-CD30 (200 ng of each
plasmid/well). To determine the transactivation effect
of the NF-κB transcription factors alone or in combin-
ation with the Meq oncoprotein on the Meq promoter
SOgE cells were transfected with plasmid mixtures
and DNA. Plasmid pUC18 was added to transfection
mixtures to give total amount of 400 ng plasmid DNA
per well whenever it was necessary. Total RNA
was isolated from transfected SOgE cells 48 h post
transfection using TRI reagent (Molecular Research
Center) following the manufacturer’s instructions.
Isolated RNA was treated with DNaseI, extracted with
phenol/chloroform, precipitated with ethanol and resus-
pended in water.
The d2EGFP mRNA levels in transfected SOgE cells
were quantified using the Platinum Quantitative RT-
PCR ThermoScript One-Step System (Life Technolo-
gies). Both, d2EGFP and 28S rRNA amplicons, were
designed using Beacon Designer (PREMIER Biosoft).
The reaction mixture consisted of 2X ThermoScript Re-
action buffer, 10 μM of each primer, 1 μM each
of probes, Platinum Taq DNA polymerase and 1 μL of
total RNA (5 ng/μL) and the total volume was made to
12.5 μL with RNAase free water as filler. Amplification
and detection was done on iCycler iQ Real-Time PCR
Detection System (Bio-Rad) with the cycle profile of
50°C for 30 min and 95°C for 5 min, followed by
45 cycles of 95°C for 15 s and 60°C for 1 min. Each
QPCR experiment included, samples (in triplicate), two
no-template controls and a dilution series (5, 10, 50,
100, 500 and 1000) of total RNA made by mixing a 10
μL aliquot from all samples). Standard curves for
d2EGFP and 28S rRNA were generated from the dilu-
tion series and the ratio of coefficient of regressionvalues (for 28S RNA and d2EGFP) was used to calculate
correction factor for PCR efficiency between these two
genes. Both d2EGFP and 28S rRNA cycle threshold (Ct)
values were subsequently normalized for correction fac-
tor for PCR efficiency. Mean Ct value for 28S rRNA was
used to normalize the d2EGFP Ct values for any volume
error. The means of the normalized Ct values were used
to compare the relative percent expression compared to
d2EGFP expression driven by the CMV promoter by
doing one way ANOVA.Gene ontology (GO) based phenotype modeling
GO was used to identify the phenotype of CD30hi and
CD30lo cells, specifically with respect to GO terms
which are associated with cancer [3]. The GO annota-
tions were obtained using tools available at AgBase [142]
and modeled as described previously in [3]. Briefly, all
the annotations those were either agonistic or antagonis-
tic to specific biological processes which included activa-
tion, angiogenesis, apoptosis, cell cycle, differentiation,
DNA damage response, migration, oxidative stress, and
proliferation and telomere maintenance [3], were
selected and the difference between the number of agon-
istic and antagonistic annotations indicated the overall
phenotype for that particular GO term. GO-modeler
based modeling for T-regulatory cells was done as
described in [6,12] for both transcriptomics and proteo-
mics data.mRNA and protein expression comparison
We calculated the fold change in amount of mRNAs
and proteins transcripts in CD30hi cells compared to
CD30lo cells in semi-quantitative manner. For micro-
array data we calculated the fold change in terms of ratio
of normalized fluorescent intensities; for proteomics
data, fold change was calculated by taking the ratio of
mean sum of XCorr of that protein in CD30hi to CD30lo
cells.Additional files
Additional file 1: Additional file 1 contains four worksheets, sheet 1
(CD30hi Vs. CD30lo protein expression): contains proteins identified
from CD30lo and CD30hi cells, worksheet 2 (ChIP identified
proteins): contains proteins identified in ChIP experiment. Worksheet
3 (NF κB isoforms subcellular locations): contains actual numbers of
peptides of different isoforms of NF-κB in nuclear and extranuclear
fractions, and worksheet 4 (Phosphorylated peptides locations) contains
actual numbers of phosphorylated and non-phosphorylated peptides
identified.
Additional file 2: Additional file 2 contains three worksheets, sheet
1 contains the results from the statistical analysis of microarray
data, sheet 2 contains expression data for only miRNAs and sheet 3
contains predicted targets genes and the relative protein
expression of the targets of the miRNAs.
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binding sites for 88 concordantly expressed host host gene
products.
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